Sandoz enters new era as standalone global leader and European champion in generic and biosimilar medicines
Spin-off from Novartis successfully completed with first trading day today on SIX Swiss Exchange; Sandoz shares included in key market indices Standalone Sandoz committed to extend leadership in stable and growing market via purpose-driven strategy